Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Polman

Showing results (171-180 of 290) with videos related to

Pageof 29
Sort By:
AJNR. American Journal of Neuroradiology|May 12, 1998
Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MRJ H van Waesberghe, M A van Walderveen, J A Castelijns, et al.
Brain : a Journal of Neurology|September 8, 2006
The usefulness of evaluative outcome measures in patients with multiple sclerosisV de Groot, H Beckerman, B M J Uitdehaag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2007
Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of diseaseH Vrenken, P J W Pouwels, S Ropele, et al.
Neurology|August 19, 2009
The challenge of follow-on biologics for treatment of multiple sclerosisS C Reingold, J P Steiner, C H Polman, et al.
Neurology|October 10, 2001
Optimizing the association between disability and biological markers in MSN F Kalkers, E Bergers, J A Castelijns, et al.
Neurology|February 13, 2001
Concurrent validity of the MS Functional Composite using MRI as a biological disease markerN F Kalkers, L Bergers, V de Groot, et al.
Archives of Neurology|November 1, 1994
4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosisC H Polman, F W Bertelsmann, R de Waal, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 19, 2013
Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosisM M Schoonheim, Jjg Geurts, O T Wiebenga, et al.
Annals of Neurology|June 14, 2000
Diagnostic criteria for primary progressive multiple sclerosis: a position paperA J Thompson, X Montalban, F Barkhof, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2004
No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosisJ N P Zwemmer, T van Veen, L van Winsen, et al.
Pageof 29

Showing results (171-180 of 290) with videos related to

Sort By:
Pageof 29
AJNR. American Journal of Neuroradiology|May 12, 1998
Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MRJ H van Waesberghe, M A van Walderveen, J A Castelijns, et al.
Brain : a Journal of Neurology|September 8, 2006
The usefulness of evaluative outcome measures in patients with multiple sclerosisV de Groot, H Beckerman, B M J Uitdehaag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2007
Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of diseaseH Vrenken, P J W Pouwels, S Ropele, et al.
Neurology|August 19, 2009
The challenge of follow-on biologics for treatment of multiple sclerosisS C Reingold, J P Steiner, C H Polman, et al.
Neurology|October 10, 2001
Optimizing the association between disability and biological markers in MSN F Kalkers, E Bergers, J A Castelijns, et al.
Neurology|February 13, 2001
Concurrent validity of the MS Functional Composite using MRI as a biological disease markerN F Kalkers, L Bergers, V de Groot, et al.
Archives of Neurology|November 1, 1994
4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosisC H Polman, F W Bertelsmann, R de Waal, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 19, 2013
Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosisM M Schoonheim, Jjg Geurts, O T Wiebenga, et al.
Annals of Neurology|June 14, 2000
Diagnostic criteria for primary progressive multiple sclerosis: a position paperA J Thompson, X Montalban, F Barkhof, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2004
No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosisJ N P Zwemmer, T van Veen, L van Winsen, et al.
Pageof 29